Zacks Investment Research upgraded shares of West Pharmaceutical Services (NYSE:WST) from a sell rating to a hold rating in a research note released on Saturday.

According to Zacks, “West Pharmaceutical Services, Inc. is a global drug delivery technology company that applies proprietary materials science, formulation research and manufacturing innovation to advance the quality, therapeutic value, development speed and rapid market availability of pharmaceuticals, biologics, vaccines and consumer healthcare products. West is the world’s premiere provider of standard-setting systems and device components for parenterally administered medicines and an emerging leader in the development of advanced formulation technologies for the transmucosal delivery of drugs. West contract manufacturing harnesses a powerful combination of innovation, technology, infrastructure and expertise to serve the pharmaceutical, medical and consumer industries. Along with more than 50 years of experience, they bring customers quality, safety and reliability in injection molding, contract assembly and finished packaging. “

Separately, ValuEngine upgraded West Pharmaceutical Services from a hold rating to a buy rating in a research note on Wednesday, October 17th.

Shares of WST stock opened at $105.39 on Friday. The company has a debt-to-equity ratio of 0.15, a current ratio of 2.94 and a quick ratio of 2.23. The company has a market capitalization of $8.16 billion, a P/E ratio of 37.91, a P/E/G ratio of 4.13 and a beta of 1.19. West Pharmaceutical Services has a 1 year low of $82.74 and a 1 year high of $125.09.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings results on Thursday, October 25th. The medical instruments supplier reported $0.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.70 by $0.06. The business had revenue of $431.70 million during the quarter, compared to analysts’ expectations of $427.55 million. West Pharmaceutical Services had a return on equity of 15.78% and a net margin of 9.06%. As a group, analysts predict that West Pharmaceutical Services will post 2.83 earnings per share for the current year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Meeder Asset Management Inc. bought a new stake in West Pharmaceutical Services during the third quarter worth $101,000. Integrated Investment Consultants LLC bought a new stake in West Pharmaceutical Services during the second quarter worth $155,000. Pendal Group Ltd bought a new stake in West Pharmaceutical Services during the third quarter worth $181,000. First Allied Advisory Services Inc. bought a new stake in West Pharmaceutical Services during the second quarter worth $200,000. Finally, Alps Advisors Inc. bought a new stake in West Pharmaceutical Services during the second quarter worth $206,000. Hedge funds and other institutional investors own 92.62% of the company’s stock.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.

Recommended Story: New Google Finance Tool and Screening Stocks

Get a free copy of the Zacks research report on West Pharmaceutical Services (WST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.